Can the MMR Vaccine Be Given During Cosentyx Therapy?
No, the MMR (measles, mumps, rubella) vaccine should not be administered during Cosentyx (secukinumab) therapy. Cosentyx, an IL-17A inhibitor used for psoriasis, psoriatic arthritis, and other inflammatory conditions, suppresses the immune system, increasing risks from live vaccines like MMR. Official prescribing information states: "Live vaccines should not be given to patients with active disease receiving Cosentyx because of the potential increased risk of infections."[1]
Why Live Vaccines Like MMR Are Avoided with Cosentyx
Live vaccines contain weakened but replication-competent viruses that can cause infection in immunocompromised patients. Cosentyx impairs immune responses, potentially leading to disseminated vaccine-strain infections. MMR falls into this category, unlike inactivated vaccines (e.g., flu shot), which are generally safe.[1][2]
What Timing Is Recommended for Vaccination?
- Before starting Cosentyx: Complete all live vaccines at least 4 weeks prior to the first dose.[1]
- During therapy: Defer live vaccines until at least 4–6 months after the last Cosentyx dose, allowing immune recovery.[1][3]
Healthcare providers may assess individual risk based on disease activity and immune status.
Safe Alternatives During Treatment
Inactivated or recombinant vaccines are permissible:
- Tdap (tetanus, diphtheria, pertussis)
- Inactivated polio (IPV)
- Pneumococcal (PCV13 or PPSV23)
- COVID-19 vaccines (mRNA or protein-based)
Annual influenza vaccine (inactivated) is recommended.[1][2]
Patient Risks and Real-World Concerns
Immunosuppression from Cosentyx raises infection risks, including from MMR in outbreaks. Case reports note rare vaccine-related infections with IL-17 inhibitors. Patients should check vaccination status pre-treatment and discuss with providers; antibody titers can confirm immunity without revaccination.[3]
Sources
[1]: Cosentyx Prescribing Information (Novartis)
[2]: CDC: Vaccination of Immunocompromised Adults
[3]: IDSA Guidelines on Vaccination in Immunocompromised Hosts